PDF herunterladen
Thromb Haemost 2008; 100(04): 521-522
DOI: 10.1160/TH08-07-0461
Editorial Focus
Schattauer GmbH

Overcoming “resistance” to aspirin and clopidogrel with tirofiban: fact or fiction?

Giuseppe Biondi-Zoccai
1   Division of Cardiology, University of Turin, S. Giovanni Battista Hospital, Turin, Italy
,
Marzia Lotrionte
2   Division of Heart Failure and Cardiac Rehabilitation, Cardiovascular Department, Catholic University of the Sacred Heart, Rome, Italy
,
Imad Sheiban
1   Division of Cardiology, University of Turin, S. Giovanni Battista Hospital, Turin, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 22. Juli 2008

Accepted 22. Juli 2008

Publikationsdatum:
22. November 2017 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints
 

  • References

  • 1 Nikolsky E, Mehran R, Dangas G. et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28: 1936-1945.
    CrossrefPubMedSuche in Google Scholar
  • 2 Biondi-Zoccai G, Lotrionte M. Aspirin resistance in cardiovascular disease. Br Med J 2008; 336: 166-167.
    CrossrefPubMedSuche in Google Scholar
  • 3 Campo G, Valgimigli M, Gemmati D. et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 2007; 50: 1132-1137.
    CrossrefPubMedSuche in Google Scholar
  • 4 Silber S, Albertsson P, Avilés FF. et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
    CrossrefPubMedSuche in Google Scholar
  • 5 Bassand JP, Hamm CW, Ardissino D. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.
    CrossrefPubMedSuche in Google Scholar
  • 6 Ivandic BT, Kurz K, Keck F. et al. Tirofiban optimizes platelet inhibition for immediate PCI in high-risk acute coronary syndromes. Thromb Haemost 2008; 100: 648-654.
    Thieme ConnectPubMedSuche in Google Scholar
  • 7 Kastrati A, Mehilli J, Neumann FJ. et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. J Am Med Assoc 2006; 295: 1531-1538.
    CrossrefPubMedSuche in Google Scholar
  • 8 Lotrionte M, Biondi-Zoccai GG, Agostoni P. et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 100: 1199-1206.
    CrossrefPubMedSuche in Google Scholar
  • 9 Stone GW, Ware JH, Bertrand ME. et al. Anti-thrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. J Am Med Assoc 2007; 298: 2497-2506.
    CrossrefPubMedSuche in Google Scholar
  • 10 Stone GW, Witzenbichler B, Guagliumi G. et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
    CrossrefPubMedSuche in Google Scholar